Evidence That Anorectal Transplantation Is the Logical Treatment for Serious Anorectal Dysfunction and Permanent Colostomy

2016 ◽  
Vol 48 (2) ◽  
pp. 497-498
Author(s):  
F.H. Ferreira Galvao ◽  
J. Araki ◽  
V.E. Seid ◽  
D.R. Waisberg ◽  
M.C. Traldi ◽  
...  
2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Sanober Nusrat ◽  
Elsie Gulick ◽  
David Levinthal ◽  
Klaus Bielefeldt

Constipation and fecal incontinence are common in patients with neuromuscular diseases. Despite their high prevalence and potential impact on overall quality of life, few studies have addressed anorectal dysfunction in patients with multiple sclerosis (MS). The goal of this paper is to define the prevalence, pathophysiology, impact, and potential treatment of constipation and incontinence in MS patients. Methods. The PubMed database was searched for English language publications between January 1973 and December 2011. Articles were reviewed to assess the definition of the study population, duration, type and severity of MS, sex distribution, prevalence, impact, results of physiologic testing, and treatments. Results. The reported prevalence of constipation and fecal incontinence ranged around 40%. Anorectal dysfunction significantly affected patients with nearly 1 in 6 patients limiting social activities or even quitting work due to symptoms. Caregivers listed toileting as a common and significant burden. The only randomized controlled trial showed a marginal improvement of constipation with abdominal massage. All other reports lacked control interventions and only demonstrated improvement in individuals with milder symptoms. Conclusion. Anorectal dysfunction is a common manifestation in MS that significantly affects quality of life. Therapies are at best moderately effective and often cumbersome, highlighting the need for simple and more helpful interventions.


1949 ◽  
Vol 77 (3) ◽  
pp. 344-348 ◽  
Author(s):  
Lester Breidenbach ◽  
Louis R. Slattery
Keyword(s):  

2018 ◽  
Vol 18 (3-4) ◽  
pp. 390-405 ◽  
Author(s):  
PEDRO CABALAR ◽  
JORGE FANDINNO ◽  
LUIS FARIÑAS DEL CERRO ◽  
DAVID PEARCE

AbstractIn this paper, we propose a variant of Answer Set Programming (ASP) with evaluable functions that extends their application to sets of objects, something that allows a fully logical treatment of aggregates. Formally, we start from the syntax of First Order Logic with equality and the semantics of Quantified Equilibrium Logic with evaluable functions (${\rm QEL}^=_{\cal F}$). Then, we proceed to incorporate a new kind of logical term,intensional set(a construct commonly used to denote the set of objects characterised by a given formula), and to extend${\rm QEL}^=_{\cal F}$semantics for this new type of expression. In our extended approach, intensional sets can be arbitrarily used as predicate or function arguments or even nested inside other intensional sets, just as regular first-order logical terms. As a result, aggregates can be naturally formed by the application of some evaluable function (count,sum,maximum, etc) to a set of objects expressed as an intensional set. This approach has several advantages. First, while other semantics for aggregates depend on some syntactic transformation (either via a reduct or a formula translation), the${\rm QEL}^=_{\cal F}$interpretation treats them as regular evaluable functions, providing a compositional semantics and avoiding any kind of syntactic restriction. Second, aggregates can be explicitly defined now within the logical language by the simple addition of formulas that fix their meaning in terms of multiple applications of some (commutative and associative) binary operation. For instance, we can use recursive rules to definesumin terms of integer addition. Last, but not least, we prove that the semantics we obtain for aggregates coincides with the one defined by Gelfond and Zhang for the${\cal A}\mathit{log}$language, when we restrict to that syntactic fragment.


Author(s):  
Marli Terezinha Stein Backes ◽  
Dirce Stein Backes ◽  
Alacoque Lorenzini Erdmann
Keyword(s):  

2011 ◽  
Vol 3 (1) ◽  
pp. 27
Author(s):  
David T. Marshall ◽  
Charles R. Thomas Jr

There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that


Sign in / Sign up

Export Citation Format

Share Document